• Bioxytran posted a net loss of $2.07 million, widening from $1.35 million a year earlier.
• Loss per share was $0.02, unchanged from the prior-year quarter.
• General and administrative expense jumped to $1.71 million from $165,642, driven by stock-based compensation of $1.29 million that included a $1.28 million performance grant to the CEO.
• Research and development expense fell to $225,479 from $349,500, while cash ended period at $463,047.
• Management said Phase 3 trials for ProLectin-M and an FDA-approved ProLectin-M trial are projected to start in third-quarter 2026, subject to adequate funding, and it believes it must raise not less than $3.7 million to continue operations for the next 15 months.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bioxytran Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-023538), on May 15, 2026, and is solely responsible for the information contained therein.